San Diego–based Ventyx Biosciences has what pharma wants, according to William Blair: two NLRP3 inhibitors for inflammatory ...

US firms SandboxAQ and MapLight Therapeutics have entered into a strategic collaboration to discover and develop potential ...

Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced a new chapter in its research and development strategy, designed to fuel the Company's next era for growth and deliver long-term value.

Every year in biopharma brings its share of grueling defeats, and 2025 was no different, especially for companies targeting ...

Discover top biotech companies for 2026, featuring emerging stars and leaders set for major clinical and regulatory ...

GSK’s Nucala receives positive CHMP opinion for treatment of chronic obstructive pulmonary disease: London, UK Monday, December 15, 2025, 16:00 Hrs [IST] GSK plc announced that ...

London: GSK has announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency ...

Cobenfy’s efficacy at treating the symptoms of patients with psychosis may vary between subgroups, according to a post-hoc ...

As per previous communication, the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) had informed Anavex about a negative trend-vote following its oral examination in ...

GSK secures FDA approval for its oral gonorrhoea drug as EMA backs expanded RSV vaccine and additional respiratory treatments ...

Neurocrine Biosciences, Inc. ( NBIX) Discusses Progress and Strategy in Neurology and Obesity R&D Programs December 16, 2025 12:00 PM EST ...

Although the research centered on mAChR4 within the gut, this signaling protein is also known to influence areas of the brain involved in habit formation, learning and addiction. Because individuals ...